Cognate interactions between antigen-presenting B and T cells play crucial roles in immunologic responses. T cells that have been activated via the crosslinking of CD3 are able to induce B cell proliferation and immunoglobulin secretion in a major histocompatibility complex-unrestricted and contact-dependent manner. We find that such activated human CD4 + T cells, but not control Ig-treated T cells, may induce normal or leukemic B cells to express B7/BB1 and significantly higher levels of CD54 intercellular adhesion molecule 1 via a process that also requires direct cell-cell contact. To discern what cell surface molecule(s) may be responsible for signalling B cells to express B7/BB1, we added various monoclonal antibodies (mAbs) specific for T or B cell accessory molecules or control mAbs to cocultures of c~-CD3-activated T cells and resting B cells. We find that only ol-CD40 mAbs can significantly inhibit the increased expression of B7/BB1, suggesting that the ligand for CD40 expressed on activated T ceils may be an important inducer of B7/BB1 expression. Subsequent experiments in fact demonstrate that cr mAbs, but not control mAbs, induce changes in B cell phenotype similar to those induced by activated T cells when the mAbs are presented on Fc"/RII (CDw32)-expressing L ceils. These phenotypic changes have significant effects on B cell function. Whereas chronic lymphocytic leukemia (CLL) B cells normally are very poor stimulators in allogeneic mixed lymphocyte reactions (MLRs), CLL-B ceils preactivated via CD40 crosslinking are significantly better presenters of aUoantigen, affecting up to 30-fold-greater stimulation of T cell proliferation than that induced by control treated or nontreated CLL-B cells. Similarly, the MLR of T cells stimulated by allogeneic nonleukemic B cells can be enhanced significantly if the stimulator B cells are preactivated via CD40 crosslinking. The enhanced MLR generated by such preactivated B ceils may be inhibited by blocking B7/BB1-CD28 interaction with CTLA4Ig. These studies demonstrate a novel, CD40-dependent pathway for inducing B cell expression of B7/BB1 and enhancing B cell antigenpresenting cell activity that can be initiated via cell-ceU contact with ot-CD3-stimulated CD4 + T cells.
Summary
Cognate interactions between antigen-presenting B and T cells play crucial roles in immunologic responses. T cells that have been activated via the crosslinking of CD3 are able to induce B cell proliferation and immunoglobulin secretion in a major histocompatibility complex-unrestricted and contact-dependent manner. We find that such activated human CD4 + T cells, but not control Ig-treated T cells, may induce normal or leukemic B cells to express B7/BB1 and significantly higher levels of CD54 intercellular adhesion molecule 1 via a process that also requires direct cell-cell contact. To discern what cell surface molecule(s) may be responsible for signalling B cells to express B7/BB1, we added various monoclonal antibodies (mAbs) specific for T or B cell accessory molecules or control mAbs to cocultures of c~-CD3-activated T cells and resting B cells. We find that only ol-CD40 mAbs can significantly inhibit the increased expression of B7/BB1, suggesting that the ligand for CD40 expressed on activated T ceils may be an important inducer of B7/BB1 expression. Subsequent experiments in fact demonstrate that cr mAbs, but not control mAbs, induce changes in B cell phenotype similar to those induced by activated T cells when the mAbs are presented on Fc"/RII (CDw32)-expressing L ceils. These phenotypic changes have significant effects on B cell function. Whereas chronic lymphocytic leukemia (CLL) B cells normally are very poor stimulators in allogeneic mixed lymphocyte reactions (MLRs), CLL-B ceils preactivated via CD40 crosslinking are significantly better presenters of aUoantigen, affecting up to 30-fold-greater stimulation of T cell proliferation than that induced by control treated or nontreated CLL-B cells. Similarly, the MLR of T cells stimulated by allogeneic nonleukemic B cells can be enhanced significantly if the stimulator B cells are preactivated via CD40 crosslinking. The enhanced MLR generated by such preactivated B ceils may be inhibited by blocking B7/BB1-CD28 interaction with CTLA4Ig. These studies demonstrate a novel, CD40-dependent pathway for inducing B cell expression of B7/BB1 and enhancing B cell antigenpresenting cell activity that can be initiated via cell-ceU contact with ot-CD3-stimulated CD4 + T cells.
B cells may play an important role in antigen presentation (1) (2) (3) (4) (5) . Cognate interactions between T and B cells may result in bidirectional stimulatory signals, allowing properly activated B cells both to induce T cell proliferation and to elicit helper activity from T cells that recognize antigen presented by B cell MHC molecules. It is important that the B cell phenotype may influence whether such cognate interactions result in either T cell activation or anergy (6) . For example, resting B cells generally are ineffective stimulators of allogeneic T cells in the mixed lymphocyte reaction (MLR) 1 unless preactivated by oMgM antibodies, PMA or LPS (7) (8) (9) . In addition, soluble monomeric antigen directed 1 Abbreviations used in this paper: CLL, chronic lymphocytic leukemia; MFIK, mean fluorescence intensity ratio; MLR, mixed lymphocyte reaction; Pl, propidium iodide; RPMI-10, penicillin-streptomycin; SM, staining media; VCAM-1, vascular cell adhesion molecule 1; VLA-4, very late antigen 4. to B cells for presentation in vivo may result in specific T cell anergy (10) . However, that same antigen may stimulate a vigorous antigen-specific immune response when delivered as a divalent molecule that can crosslink B cell surface Ig. Recent studies have indicated that the interactions between B and T cell surface molecules, such as intercellular adhesion molecule 1 (ICAM-1) (CD54) and LFA-1 (CD11a/CD18), LFA-3 (CD58) and CD2, very late antigen 4 (VLA-4) (CDw49d) and vascular cell adhesion molecule 1 (VCAM-1), and B7/BB1 and CD28, play important roles in B-T cell conjugate formation and in patterning the response to B cell-presented antigen (11) (12) (13) (14) (15) . In particular, B cell expression of B7/BB1, induced by slg crosslinking (16, 17) , may activate antigen-specific T cells to secrete IL-2 and to proliferate in response to B cell-presented antigen, thereby possibly preventing the induction of antigen-specific T cell anergy (6, (18) (19) (20) (21) .
Little is known about how activated T cells may affect expression of these important B cell accessory molecules. Prior studies demonstrated that T cells, activated by TCR crosslinking with o~-CD3 mAb or Con A may induce B cell proliferation, differentiation, and Ig secretion in an MHC and antigen-independent manner that requires direct T-B cell contact (22) (23) (24) (25) (26) (27) (28) . These studies primarily addressed how such activated T cells may induce B cells to differentiate into Igsecreting cells. However, because of the pivotal role that surface phenotype may play in determining whether a B cell can function as a stimulatory APC, we assayed for changes in the levels of accessory molecules expressed by B cells after coculture with control Ig-treated or ot-CD3-activated T cells.
To examine the changes induced by activated T cells on relatively homogeneous populations of resting B cells, we performed initial studies using chronic lymphocytic leukemia (CLL) B cells. CLbB cells coexpress CD19, CD20, CD40, CD45, and class I and II MHC antigens, and, like a subset of normal B cells, are CD5 § (29) (30) (31) (32) . The leukemia cells from most patients express surface IgD and/or lgM and have levels of CD54 and CD58 that are comparable with those of normal resting B cells (33) . CLL-B cells are poor stimulators in autologous or allogeneic MLR (34, 35) . Arguably consistent with this, CLL-B cells express low levels of CDlla and VLA-4 (36, 37) , and little to no B7/BB1 (16) . Although CLL-B cells are similar in many respects to normal resting B cells, we performed parallel experiments with normal peripheral blood and tonsillar B cells to examine whether any noted effects were peculiar to leukemic B cells.
Materials and Methods
Antibodies. 64.1, a murine IgG2a c~-CD3 mAb, was provided by Bristol-Myers Squibb (Seattle, WA). G28-5 (a murine IgG1 c~-CD40 mAb, [38] ) was a gift from Dr. Edward Clark (University of Washington, Seattle, WA). Murine mAbs specific for CDlla (IgG1 anti-LFA-1), CD54 (IgG1 anti-ICAM-1), CD58 (IgG2a anti-LFA-3), HLA-DR (IgG2b), or CDw49d (IgG1 anti-VLA-4) were purchased from AMAC, Inc. (Westbrook, ME). PE-conjugated cr (B4, a murine IgG1) was purchased from Coulter Immunology (Hialeah, FL). MOPC21 (marine IgG1) was purchased from Caltag, Inc. (South San Francisco, CA). RPC-5 (murine IgG2a) was purchased from Calbiochem Novabiochem Corp. (La Jolla, CA). c~-CD14 (done LeuM3, a murine IgG2b) and cr (done Leulla, a murine IgG1) were purchased from Becton Dickinson & Co. (San Jose, CA). ~-B7/BB-1 (clone L307.4, a murine IgG1) was purchased from the Advanced Cellular Biology Division of Becton Dickinson & Co. (San Jose, CA) and conjugated to FITC as described (39) . HB57 (murine IgG1 cr IgM) and W6/32 (murine IgG1 ~-HLA class I) producing hybridomas were obtained from American Type Culture Collection (Rockville, MD), and mAbs were purified from ascites as described (40) . The CTLA4Ig human Ig-recombinant molecule (41) , was a gift from Dr. Peter Linsley (Oncogen Division, Bristol-Myers Squibb). Goat o~-human IL-4 was purchased from R & D Systems, Inc. (Minneapolis, MN).
Cell Purification. Human T and B cells were purified from burly coats obtained from normal donors at the San Diego Blood Bank (San Diego, CA). PBMC were isolated by centrifuging over Histopaque 1077 (Sigma Immunochemicals, St. Louis, MO) and monocytes depleted by adherence to plastic culture flasks for 2 h in a 37~ 5% COs incubator in RPMI-1640 media plus 10% FCS, 4 mM t-glutamine, and 100 U/ml penicillin-streptomycin (hereafter referred to as RPMI-10). Monocyte-depleted PBL were incubated with antibodies directed at B cells (c~-CD19), NK cells (c~-CD16), and monocytes (c~-CD14), at 1 #g of mAb per 106 estimated target cells, for 30 rain at 4~ washed, and incubated with sheep ~-mouse IgG-conjugated magnetic beads (Dynal, Inc., Great Neck, NY) at a bead to target cell ratio of 7:1 for 1 h, rocking, at 4~ Magnetic depletion of bead-bound cells resulted in >95% pure CD3 ~ T cells, as determined by FACS | analysis (Becton Dickinson & Co.). Normal B cells were purified from tonsil samples and peripheral blood with magnetic beads as described above, substituting c~-CD3 mAb for c~-CD19. CLL PBMC samples were purified only if B cells constituted <95% of the total cells. In normal cell samples, we generally obtained populations consisting of 80-95% CD19 § B cells. Cells were used fresh or viably frozen in FCS plus 10% DMSO in liquid nitrogen before use.
Activated T Cell Assay.
T-B cocultures were performed using a protocol modified from that described by Tohma and Lipsky (26) . 12-weU culture plates (Coming Inc., Coming, NY) were coated with c~-CD3 mAb (64.1) or control IgG2a mouse myeloma protein (RPC-5) at 100 ng/ml in 50 mM Tris buffer, pH 8.5, at room temperature for 2-4 h (0.5 ml/well). Wells were washed thoroughly with sterile PBS followed by RPMI-10. Purified normal T cells were suspended at 5 x 106/ml in RPMI-10 and treated with mitomycin C (Sigma Immunochemicals) at a concentration of 50 #g/ml for 1 h at 37~ to prevent proliferation. T cells were then washed 4 times with 1KPMI-10, plated onto mAb-coated wells at 6 x 106/well, and allowed to adhere for 1 h at 37~ CLL or normal B cells were added in RPMI-10 at 2 x 106 cells/well. Cells were cultured at 37~ in 5% CO2, and then harvested after 48-72 h for flow cytometric analysis.
MuhilmrameterFlow Cytometric Analysis. Cells were washed and then suspended in staining media (SM; consisting of lx HBSS, 3% BSA, .01% NAN3, and 1/~g/ml propidium iodide [PI]) with saturating amounts of FITC-or PE-conjugated mAbs against various cell surface antigens or isotype-specific control mAbs. After 30 min at 4~ cells were washed in PI-deficient SM and analyzed on a flow cytometer (FACScan| Becton Dickinson & Co.). Dead cells staining with PI were excluded from analysis. B cells were distinguished from cocultured T cells by electronic gating on cells staining with CD19-PE. The expression of all other cell surface markers was determined by staining with FITC-conjugated mAbs, as described above.
CDW32-L Cell Assay.
We employed a modified version of the B cell in vitro culture system described by Banchereau ~t al. (42) . Briefly, CDw32-expressing murine fibroblast cells (CDw32-L cells) obtained from the American Type Culture Collection (Rockville, MD), were suspended at 5 x 106/ml and then treated with 100 #g/ml mitomycin C in RPMI-10 for 1 h at 37~ These cells then were washed four times in PBS plus 50% RPMI-10. In assays for FACS | analysis of surface phenotype changes, 5 x 105 CDw32-L cells in 0.5 ml RPMI-10 per well were plated into a 24-well culture plate (Coming Inc.) and allowed to adhere for/>1 h at 37~ B cells then were added at 2 x 10 ~ per well in final volume of 1 ml. Various mAbs and/or recombinant human IL-4 (rhlL-4; Biosource International, Camarillo, CA) were added at various concentrations. Cultures were incubated 48-72 h before harvesting for FACS | analysis.
MLR. CLL-B cells were stimulated for 48 h with cr or control mAb plus IL-4 as above, but using 6-well culture plates with 1.5 x 106 CDw32-L cells/well and 6 x 106 B cells/well in a total volume of 4 ml RPMI-10. B cells were separated from ad-herent CDw32-L cells by gently rinsing wells with RPMI-10, resulting in >99% pure leukemic B cells as assessed by FACS | analysis. B cells were treated with mitomycin C as above, washed four times in KPMI-10, and then suspended in RPMI plus 10% pooled human AB serum (RPMI-10 hAB; GIBCO BILL; Gaithersburg, MD). B cells were plated with various blocking or control mAbs in 150 #1 KPMI-10 hAB in triplicate in 96-well round-bottomed plates (Corning Inc.) at 105 to 400 cells/well to give final responder T cell to stimulator B cell (R/S) ratios of between 1:1 and 25:1. After allowing mAbs to bind for 1 h at 37~ responder allogeneic normal T cells, isolated as described above, were added at 10S/well in a final total volume of 200/zl, and plates were incubated at 37 ~ 5% CO2 for 5 d. Proliferative response was measured by pulsing the cultures with 1 /xCi/well [3H]thymidine (ICN Biomedicals, Inc., Costa Mesa, CA) 18 h before harvesting onto glass fiber filters (PHD Cell Harvester; Cambridge Technology, Inc., Watertown, MA). Filter-bound [3H]thymidine that had been incorporated into newly synthesized DNA was measured using a scintillation counter (model LS1 801; Beckman Instruments, Inc., Fullerton, CA).
Results

B Cell Surface Phenotype Changes Induced by Activated
Cells. CLbB cells or normal human B cells were cultured alone or with allogeneic, mitomycin C-treated T cells previously plated in culture wells coated with either cr mAb (64.1) or control mouse IgG of the same isotype. As described (26, 43) , a-CD3 mAb-coated plates may induce T lymphocytes to become "activated T cells" (T, cells), affecting increases in T cell intravascular Ca 2+ ([Ca 2+ ]i), phosphatidylinositol turnover, protein tyrosine kinase activity, proliferation, and expression of HLA-DR and CD25 (44) (45) (46) (47) (48) . The term "resting T cells" (T~ cells) is used to describe mitomycin C-treated T lymphocytes cultured in control Ig-coated wells. Flow cytometric analyses indicated that, whereas <10% of Tr cells expressed CD25 and/or HLA-DR, >50% of the T, cells used in these studies expressed these T cell activation antigens (data not shown). B cells cultured either alone or in control Ig-coated wells or with Tr or T, cells were examined by flow cytometry after 48 h in culture. We find that B cells cocultured with T, cells dramatically increase their expression of CD54 (ICAM-1) and B7/BB1 (Fig. 1 C) . B cells cocultured with T, cells also manifest moderate increases in surface expression of CD11a and CD58, compared with B cells cultured alone ( Fig. 1/t) . On the other hand, B cells cocultured with T, cells displayed minimal changes in their expression levels of B7/BB1, CD54, CDlla or CD58 ( Fig.  1 B) , as did B cells cultured in o~-CD3 mAb-coated wells without added T cells (data not shown).
To compare changes in expression levels of these B cell antigens within and across experiments, we computed the mean fluorescence intensity ratio (MFIR) in each staining experiment for each antigen. The MFIR for a given antigen is defined as the mean fluorescence intensity (MFI) of gated B cells stained with an antigen-specific FITC-conjugated mAb divided by the MFI of such cells stained with a FITC-conjugated isotype control mAb of irrelevant specificity. For example, B cells cocultured with Ta cells in the experiment depicted in (Fig. 2) . In contrast, CD8 + T, cells induced minimal changes in B cell expression of B7/BB1, similar to that induced by CD8 + or CD4 + T~ cells (Fig. 2) .
Induction of B7/BB1 Requires Direct T-B Celt Contact.
Previous studies demonstrated that the stimulatory effects of o~-CD3-activated T cells on B cell proliferation and Ig production were dependent on direct cell-cell contact (25, 26) . To examine whether the increased expression of B7/BB1 was mediated by soluble factors or required cell-cell contact, we cultured CLL-B cells together with T, or Tr cells, or in chambers separated from the T cells by membranes that are permeable to particles ~<0.4 #m in diameter (Transwell | inserts; Costar Corp., Cambridge, MA). We find that direct contact with T, cells results in a B7/BB1 MFIR of 3.3, as compared to B7/BB1 MFIRs of 1.4, 1.2, and 1.5 induced by contact with Ta supernatant, T~ cells or T, supernatant, respectively (average of two experiments) (Fig. 3) . The suboptimal T~-mediated induction of B7/BB1 in these experiments may be due to dilution of cells into the larger tissue culture wells necessary to accommodate the Transwells | Maximal increases in CD54 expression are also dependent on direct T,-B cell contact. Whereas contact with T, cells or supernatants ofT-B coculture increased CD54 MFIRs twoto fourfold, direct contact with T, cells induced 20-fold increases in CD54 MFIR. These results suggest that a cell surface molecule(s) is expressed on T cells upon ol-CD3 crosslinking which may induce B cells to express B7/BB1 and other surface molecules upon cell-cell contact.
The Induction of B7/BBI Is Blocked by cr-CD40 mAbs.
To discern what cell surface molecule(s) may be responsible for Ta-B cell interaction, we added each of several mAbs specific for T and/or B cell accessory molecules to cocultures of B and T, cells. We find that soluble a-CD40 mAb (G28-5), but not mAbs specific for HLA class I or II, CD11a (LFA-1), or CD58 (LFA-3), can significantly inhibit the induction of CLIMB cell surface B7/BB1 expression by T, cells (Fig. 4) . In five experiments, we noted that cx-CD40 mAb affected Fluorescence Intensity of B7/BB1 A modest reduction (13 _+ 6%) in the level of Ta cell-induced B7/BB1 also was noted when saturating amounts of mAbs specific for CDw49d (VLA-4) were added to the cultures (mean of three experiments) (Fig. 4) . However, this inhibition was not significant (p >.05). In contrast, saturating amounts of ol-CDlla or c~-HLA-DR mAbs, even at concentrations 20 times higher than that needed for maximal inhibition by ot-CD40, had no effect on T~-cell-induced expression of B7/BB1 or CD54 (Fig. 4) . Although not necessary for the ol-CD40-induced phenotypic changes, exogenous rhlb4 augmented the effect of CD40 crosslinking in a dose-responsive manner (Fig. 6 b, filled  squares) . IL-4, alone or in combination with control mAbs, did not change the level of B7/BB1 expressed by CLL-B cells when cultured without T~ cells or ot-CD40 mAbs and CDw32-L cells (Fig. 6 b, open square) . Furthermore, ot-hlb4 neutralizing antibody at ~<5 #g/ml did not reduce the Changes in the expression levels of other surface antigens also are observed in o~-CD40-stimulated CLL or normal B cells. The CD58 MFIR increased ",~14-fold, whereas the CD11a MFIR increased only 1-1.8-fold over that seen in control-treated cells (data not shown). In addition, the CD23 MFIR increased up to 80-fold, similar to the increase observed for CD54 (data not shown). However, the normally high expression levels of class I and II MHC and CD45 on CLL-B cells were not affected by CD40 crosslinking (data not shown).
Crosslinking CD40 Induces Changes in Surface Phenotype
The kinetics of oe-CD40 mAb or Ta cell-contact-mediated induction of CD54 or B7/BB1 expression were similar. As with T~ cell-mediated stimulation, B7/BB1 increases were noticeable only after 18-24 h of stimulation with ol-CD40 plus IL-4, reaching a maximum sevenfold increase in expression level after ,,o72-h culture (Fig. 7) . The increase in B cell expression of CD54 followed similar kinetics, increasing nearly twofold at 6 h, fivefold at 12 h, and achieving a maximum 70-fold increase after ~70 h of culture. B cells cocultured with o~-CD40 and CDw32-L cells for prolonged periods (i>120 h) did not manifest any further increases in expression of B7/BB1 or CD54 (data not shown). Finally, cell proliferation was not required, as mitomycin C did not affect the ability of B cells to manifest increases in B7/BB1 or CD54 MFIRs upon coculture with c~-CD40 mAbs and CDw32-L cells (data not shown).
Enhanced Expression of BT/BB1 and other Accessory Molecules Has Functional Significance.
To determine whether the expression of B7/BB1 and other surface molecules induced by CD40 crosslinking enhanced the capacity of B cells to act as stimulatory APCs, we examined resting and o~-CD40-activated CLb or normal B cells for their ability to present alloantigen to normal T cells derived from unrelated donors. Control Ig-treated or nontreated CLL-B cells are very poor stimulators of allogeneic normal T cells in the MLR (Fig.  8 A) . Upon cocuhure with cr plus IL-4 and CDw32-L cells, however, CLL-B cells became significantly better presenters of aUoantigen, affecting a significant increase in T cell [3H]thymidine uptake over that observed in T cells cocultured with control-treated CLL-B cells (Fig. 8 A, top two bars, p = .002). The ability of normal peripheral blood B cells to stimulate allogeneic T cells also was enhanced significantly by treatment with oe-CD40 presented on CDw32-L cells in the presence of exogenous IL-4 ( Fig. 8 B, top two bars, 
p = .02).
Various mAbs were added at the beginning of the MLKs to determine whether they could inhibit the APC function of ovCD40-stimulated allogeneic B cells (Fig. 8, A and B) . All blocking reagents were used at concentrations that gave maximal inhibition and/or cell surface staining in preliminary experiments. The proliferation of T cells in response to o~-CD40-stimulated B cells was not affected significantly by addition of control mouse or human IgG of irrelevant specificity (data not shown). However, addition of CTLA4Ig, a recombinant human Ig capable of blocking B7/BB1/CD28 ( Fig. 8) . Such combinations completely abrogated the allo-APC activity of stimulated leukemic or normal B cells. We also find that CLbB cells stimulated by contact with T~ cells, but not with T~ cells, exhibit enhanced MLR stimulatory capacity, similar to what was observed with c~-CD40-stimulated CLL-B ceUs. CLbB ceUs were cultured alone or with Ta or Tr cells. After 48 h, B ceils were isolated to >95% purity by magnetic bead depletion of T cells. In MLRs, B ceils previously cultured with T~ cells stimulated allogeneic T cells to incorporate significantly more [3H]thymidine (9,546 _+ 383 cpm) than did B ceils previously cuhured alone (2,480 _+ 1,579; p = 0.02) or with Tr cells (1,424 _+ 598; p < 0.01). It is unlikely that residual T~ cells were responsible for inducing this increase in MLR stimulatory activity, as the responder T cells in these MLRs were autologous to the T~/T~ cells used to stimulate CLL-B cells in culture. Also, the MLR response against unseparated B-T, cocultured cells was less than that against purified B cells alone. As in MLRs using c~-CD40-stimulated B cells, the measured T cell proliferation against T~ cell-stimulated B cells was reduced by/>75% in MLR culture wells containing CTLA4Ig (data not shown). , c~-CD58 mAb (CD58), CTLA41g and tx-CDlla mAb (B7 + CDlla), CTLA4Ig and ct-CD58 mAb (B7 + CD58), o~-CDlla mAb and tx-CD58 mAb (CDIla + CD58) or CTLA41g, o~-CDlla mAb, and ct-CD58 mAb (B7 + CDIla + CD58). There were no significant differences between responses to c~-CD40-stimulated B cells alone or in the presence of control human or mouse IgG (data not shown). Results are reported as the mean cpm of triplicate wells for each condition (error bars = SD).
interactions (41) , inhibited 82% of the MLR against stimulated CLL-B cells (Fig. 8 A) and 76% of the MLR against stimulated normal B cells (Fig. 8 B) (p <0.01). Addition of o~-CDlla inhibited T cell proliferation in response to stimulated leukemic or normal B cells by 46 or 50%, respectively (p <0.05) (Fig. 8) . In contrast, cr mAbs did not significantly inhibit the MLRs, affecting only a 20 or 36% reduction in [3H]thymidine uptake by T cells cocultured with stimulated leukemic or normal B cells, respectively. The combination of ol-CDlla together with ot-CD58, however, was strongly inhibitory (p <.01), affecting a >--88% inhibition of MLRs (Fig. 8) . Even more effective were combinations of CTLA4Ig and ct-CD11a, with or without ot-CD58
Discussion
We demonstrate that normal human CD4 + T cells which are activated by mAb-mediated crosslinking of CD3, but not T cells stimulated with nonspecific control Ig, may induce normal or leukemic B cells to express substantially higher levels of B7/BB1 and CD54, two accessory molecules that are important in T-B conjugate interactions. Such changes are not secondary to the outgrowth of BT/BB1-and CD54-expressing B ceils, as mitomycin C-treated B ceils that are unable to divide also may be induced to express higher levels of these surface antigens. Also, the changes in B cell phenotype were not secondary to a direct effect of FcR crosslinking due to the solid phase 64.1 mAb, as control Ig of the same isotype as 64.1 (IgG2a) failed to stimulate B ceils in T-B cocultures. Furthermore, even the 64.1 mAb did not induce surface phenotype changes in B cells unless CD4 § T cells also were present. Finally, to affect substantial changes in phenotype, the B cells must be cultured in direct contact with TR cells, as evidenced by the failure of soluble factors from the supernatants of Ta cells or Ta-B cocultures to induce B cell expression of B7/BB1. Previous studies demonstrated that Ta cell-induced B cell proliferation and Ig secretion also were contact dependent (22) (23) (24) (25) (26) (27) (28) . Collectively, these findings indicate that a cell surface molecule(s) may be induced on CD4 + T cells that can stimulate resting B cells to undergo a variety of phenotypic and/or functional changes.
Crosslinking CD40 induces B cell phenotypic changes similar to those caused by contact with Ta cells. We find that soluble mAbs against CD40, but not mAbs against any one of a variety of other B cell accessory molecules, can inhibit the T, cell-induced increase in expression of BT/BB1 or CD54 on CLL-B cells. On the other hand, c~-CD40 mAbs, when presented on a membrane matrix of CDw32-L cells, can affect changes in the expression of B cell accessory molecules that mimic those induced by coculture with T~ cells. Collectively, these studies suggest that CD40 crosslinking may be necessary and sufficient for Ta cell-induced expression of B7/BB1 and other accessory molecules on resting B cells.
Prior studies also noted that B cell expression of CD54 may be enhanced by treatment with ot-CD40 mAbs (49) . Similar to what we observed in the current study, these investigators noted that normal B cells cocultured with soluble c~-CD40 mAbs may express approximately threefold greater levels of CD54 than those of control or untreated B cells. However, we find that ot-CD40 mAbs in the presence of CDw32-transfected L cells may affect a greater than 50-fold increase in normal or leukemic B cell expression of CD54. This augmented effect likely is secondary to the crosslinking of CD40 that is achieved by the ot-CD40 mAb when delivered on a membrane matrix of the CDw32-L cells. This crosslinking may more closely mimic the signal achieved through cognate T~-B cell interactions.
Earlier studies demonstrated that crosslinking surface Ig or class II MHC molecules induced resting B cells to express B7/BB1 (16) (17) (18) . However, the greater than seven or fivefold increase in the expression of B7/BB1 that we observed upon crosslinking CD40 either with o~-CD40 mAb or T~ cells, respectively, are greater than three times the maximum increase in expression of this surface antigen that we could affect by crosslinking slgM or HLA-DR. Our results demonstrate the existence of a novel, CD40-dependent mechanism for inducing B7/BB1 expression on B cells that appears more effective than these previously reported stimuli.
Other investigators who studied B cell proliferation and Ig secretion induced by activated T cells also identified surface molecule(s) that may be involved in T~-B cell contact-dependent activation. Tohma and Lipsky (26) noted that mAbs that block CDlla/CD54 interactions could inhibit T~ cell-induced B cell proliferation, with the caveat that T~ cells unable to express CDlla retained the ability to stimulate B cells. In contrast, we find that ot-CDlla mAb, even at high concentrations, cannot inhibit T~ cell-induced B7/BB1 expression. Our results are consistent, however, with more recent studies by Noelle et al. (50) , who demonstrated that blocking CD40 interaction with its coligand, a type II membrane glycoprotein recently identified on activated T cells (51), could inhibit T, cell-mediated B cell DNA, RNA, and Ig synthesis. These results support the hypothesis that the B cell stimulation induced by activated T cells, whether measured as proliferation, Ig synthesis, or changes in surface phenotype, is dependent primarily on a CD40-transduced signal(s).
Previous work demonstrated that ot-CD40 mAb presented by CDw32-L cells could induce either normal or CLL-B cells to proliferate and secrete Ig in the presence of exogenous IL-4 (42, 52, 53) . IL-4 is noted to increase B cell expression of CD40 and to act as a costimulatory cytokine for anti-Ig-induced increases in [Ca z+ ], (54) . Although this cytokine may enhance the effects of CD40 crosslinking, we find that exogenous IL-4 is not necessary for e~-CD40-induced B cell expression of B7/BB1. Moreover, neutralizing c~-IL-4 antibody could not inhibit B cells from expressing increased levels of B7/BB1 or CD54 when cultured with either T~ cells, or CDw32-L cells and a-CD40 mAbs. Collectively, these studies indicate that IL-4, although capable of augmenting the signalling induced by CD40 crosslinking, is neither necessary nor sufficient to affect the phenotypic changes that we observed on B cells exposed to activated T cells.
In addition to the increased expression of B cell accessory molecules induced by CD40 signalling, a crucial finding of the present work is that such T~ cell-induced changes have functional significance for B cell APC capacity. Previous studies indicated that small resting B cells are poor APCs for primary responses, but may be effective after the responding T cell population has been activated (7, 55) . We find that T~ cells (or cr mAbs and CDw32-L cells) in fact may induce changes in CLL cells or normal resting B cells that make these cells significantly better presenters of alloantigen. In this regard, induced expression of B7/BB1 appears to be a crucial factor. CTLA4Ig, a hybrid recombinant molecule that can bind B7/BB1 and thereby block B7/BB1-CD28 interactions (41, 56) , can affect >--75% inhibition of the MLR between stimulated CLL or normal B cells and allogeneic T cells. Increased expression of CD54, or its coligand CDlla, also may be important, as c~-CD11a mAbs inhibited the MLR >45% when used alone, but >95% when combined with CTLA4Ig. This conclusion is in agreement with other studies demonstrating that expression of B7/BB1 or CD54 is important in effecting allogeneic T cell proliferation (18, 19, 41, 49, 57) . Collectively, these functional studies support the general hypothesis that activated T cells that express the CD40 ligand may not only "help" B cells differentiate into Ig secreting cells, but also may induce B cells into becoming stimulatory APCs of other resting T ceils.
In this regard, it is noteworthy that CD40 also may be expressed on thymic epithelial cells (58) and dendritic cells (59) , either of which may be involved in T cell development and/or activation. Already, CD40 crosslinking on thymic epithelial cells has been noted to induce production of GM-CSF (58) . Conceivably, these cells also may receive inductive signals from CD40 ligand-expressing T cells that could enhance their capacity to act as stimulatory APCs.
That T cells activated by TCR crosslinking acquire the capacity to induce B7/BB1 expression on resting B cells may have implications for the generation of normal immune responses, the maintenance of self-tolerance, and the initiation and/or progression of autoimmmune disease. Activated T cells may induce expression of B7/BB1 and other accessory molecules on resting B cells in an antigen-independent manner. Such stimulated B cells may engage nonactivated T cells specific for an antigen(s) presented by such cells. This, in turn, may induce CD40 ligand expression on these previously nonactivated antigen-specific T cells, allowing for an amplification of both the T and B cell immune response. However, should autoantibody-produdng B cells interact with activated T cells, then such cells may be able to stimulate T cells that are reactive to B cell-presented self-antigens, similar to B7/BB1-expressing APCs that encounter T cells specific for non-self antigens (18, 20, 21) . Indeed, Lin et al., and Mamula et al. have noted that activation of autoreactive B ceils may break T cell tolerance to self-antigens. This mechanism also may contribute to the loss of self-tolerance that sometimes accompanies persistent and/or repeated challenge with antigen, such as in adjuvant-or collagen-induced arthritis (62, 63) . In this scenario, not only may autoantibodies be produced, but also, self-reactive T cells may become activated, thus potentially fueling a sustained autoimmune response.
Eynon and Parker (10) noted that in vivo challenge with the soluble, monomeric antigen (F[ab] fragments of rabbitor-mouse IgD) resulted in antigen-specific T cell anergy, whereas challenge with divalent F(ab')2 rabbit-o~-mouse IgD antigen resulted in a vigorous immune response to rabbit Ig. In the absence of slg crosslinking, they propose that B cells may present antigen in a fashion that induces antigen-specific T cell anergy. Whatever TCR crosslinking occurs on antigenspecific T cells as a consequence of their interaction with such APCs may not be suffident to induce these cells into becoming like Ta 
